摘要
本文分析了甲亢^（131）Ⅰ治疗前后血清TGA、TMA测定结果与甲减发生的关系。77例前后对照资料表明:在治疗前抗体阳性组和阴性组中甲减发生率分别为12.5％及14.2％,甲减组与非甲减组抗体阳性率分别为70.0％及73.1％,均无显著性差异;^（131）Ⅰ治疗后抗体阳性组和阴性组中甲减发生率分别为6.7％及17.0％,甲减组与非甲减组抗体阳性率分别为20.0％及41.8％,显然抗体阳性对于甲减的发生无影响;同时发现^（131）Ⅰ治疗后46.4％的患者TGA、TMA转阴,而疗前为阴性者疗后无1例出现阳性。427例疗后患者抗体测定结果也与甲亢疗效无关。据此,我们认为甲亢患者TGA、TMA阳性不能作为禁忌^(131)Ⅰ治疗的指征。
The relation between serum anti-thy-roidism (TGA), anti-microsome (TMA) and hy-pothyroidism following 131I therapy for hyperthy-rodism was analysed. 77 patients were studied by contrasting the pre-treatment with post-treatment, the results showed that the incidence of hypothyroidism in positive and negative groups of antibodies before 131I therapy was 12.5% and 14.1%, respectively; the positive rate of antibodies in cases of hy-pothyroidism and non-hypothyroioism was respectively 70% and 73. 1%. After 131I treatment, the incidence of hypothyroidism in positive and negativegroups was 6. 7% and 17.0% , respectively; the positive rate of antibodies in cases of hypothyroidism and non-hypothyroidism was respectively 20.0% and 41.8%. Obviously, the incidence of hypothyrodism was not affected by antibodies. Following 131I therapy, 46.4% cases from positive became negative and no one case turned into positive in pre-treatment negative patients, there was no correlation between the therapeutic effects and positive rate of antibodies in 427 patients after 131I treatment. These data suggest that TGA, TMA can not be used as an index of contraindication with 131I treatment for hyperthyrodism.
出处
《西安医科大学学报》
CSCD
1995年第2期156-157,167,共3页
Journal of Xi'an Medical University(Chinese)
